Autoimmune Disorders
Welcome to this years Autoimmune Disorders session. Program chairs and moderators: Dr. Vanda Lennon (MC), Dr. Elisabet Svenugsson (KI), Dr. Vilija Oke (KI), Dr. Eoin Flanagan (MC) and Dr. Helena Idborg (KI)
8:30 - 9:25 am (US CT)/15:30- 16:25 pm (Sweden)
SESSION 1 - Rheumatoid Arthritis
Welcome and overview of Karolinska Institutet’s program and Mayo Clinic collaborative projects: Rheumatologic emphasis (10 min)
- Chairs
The metabolic signature of pro-inflammatory macrophages in rheumatoid arthritis (15 min)- Dr Tuantuan Zhao, MC
Neuroimaging biomarkers differ between patients with and without rheumatoid arthritis: results (15 min)- Dr. Elena Myasoedova, MC
Characterization of humanized mice expressing auto-reactive T cell receptor (TCR) sequences isolated from rheumatoid arthritis patients (15 min)- Dr. Bruno Raposo, KI
9:30 - 10:30 am (US CT)/ 16:30- 17:30 pm (Sweden)
SESSION 2 - Rheumatoid Arthritis and Inflammatory myopathies
Persistence to methotrexate treatment in early rheumatoid arthritis has a familial component (15 min)
- MSc. Anton Öberg Sysojev, KI
T cells in early RA synovia are predominantly CD4+ with a broad repertoire (15 min)- MD Sara Turcinov, KI
HLA-DRB1 associations with autoantibody-based clusters in idiopathic inflammatory myopathies (15 min)- Dr. Valérie Leclair, KI
Autoantigenic properties for the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies (15 min)- Dr. Antonella Notarnicola, KI
9:15 - 10:10 am (US CT)/16:15- 17:10 pm (Sweden)
SESSION 3 - Systemic Lupus Erythematosus
High urinary and renal expression of IL-16 in lupus nephritis (15 min)
- Dr. Vilija Oke, KI
The impact of remission and low disease activity attainment on health-related quality of life in two phase III clinical trials of Belimumab in SLE (15 min)- Shahrzad Kia Komujuni, KI
No evidence of rebound MS disease activity with presence of CD20+ T cells at B-cell reconstitution after treatment with rituximab (15 min)- Dr. Nicolas Ruffin, KI
Early changes in circulating B-cell subsets as markers of clinical improvement or flare during belimumab therapy in SLE (15 min)- Dr. Ioannis Parodis, KI
10:15 - 11:15 am (US CT)/17:15- 18:15 pm (Sweden)
SESSION 4 - Inflammatory diseases, neuromyelitis optica and sarcoidosis
Small Intestinal axis for treating inflammatory diseases (15 min)
- Dr. Veena Taneja, MC
Diagnostic Value of Aquaporin-4-IgG Live Cell Based Assay in Neuromyelitis Optica Spectrum (15 min)- Dr. Vyanka Redenbaugh, MC
Lifestyle-related risk factors for sarcoidosis: a nested case-control study (15 min)- MSc. Marina Dehara, KI
Discussions and concluding remarks (5 min)Asynchronous poster session
Welcome to this years asynchronous poster session within the KI-Mayo Conference 2021. Click here to enter the asynchronous poster session within Autoimmune Disorders